share_log

Avalo Therapeutics | DEFA14A: Others

Avalo Therapeutics | DEFA14A: Others

Avalo Therapeutics | DEFA14A:其他
美股sec公告 ·  06/27 07:07
Moomoo AI 已提取核心信息
Avalo Therapeutics, Inc., a biotechnology company listed in the United States, has filed definitive additional materials with the Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, pursuant to Section 14(a) of the Securities Exchange Act of 1934, is a standard procedure for companies preparing for upcoming shareholder meetings where proxy materials are provided to shareholders. Avalo Therapeutics confirmed that no filing fee was required for this submission. The materials filed are intended to provide shareholders with additional information ahead of the company's decision-making process.
Avalo Therapeutics, Inc., a biotechnology company listed in the United States, has filed definitive additional materials with the Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, pursuant to Section 14(a) of the Securities Exchange Act of 1934, is a standard procedure for companies preparing for upcoming shareholder meetings where proxy materials are provided to shareholders. Avalo Therapeutics confirmed that no filing fee was required for this submission. The materials filed are intended to provide shareholders with additional information ahead of the company's decision-making process.
生物技术公司Avalo Therapeutics, Inc.在美国上市,已经向美国证券交易委员会(SEC)提交了明确的额外材料,作为其代理声明的一部分。根据1934年证券交易法第14(a)条规定,此申报是为参与即将举行的股东会议做准备的公司进行的标准程序,届时会向股东提供代理材料。Avalo Therapeutics证实此次提交不需要提交任何文件费用。提交的材料旨在在公司决策过程前为股东提供更多信息。
生物技术公司Avalo Therapeutics, Inc.在美国上市,已经向美国证券交易委员会(SEC)提交了明确的额外材料,作为其代理声明的一部分。根据1934年证券交易法第14(a)条规定,此申报是为参与即将举行的股东会议做准备的公司进行的标准程序,届时会向股东提供代理材料。Avalo Therapeutics证实此次提交不需要提交任何文件费用。提交的材料旨在在公司决策过程前为股东提供更多信息。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息